Verana Health®

DATASHEET
Acute Myeloid Leukemia



Qdata® Acute Myeloid Leukemia (AML) is an exclusive dataset offering a comprehensive view of how AML is diagnosed and treated across care settings, including treatment approach, transplant eligibility, and patient outcomes over time.

Verana Health® powers oncology research with high-quality real-world data sourced from curated electronic health records and linked data sources at leading cancer centers across the US. Built specifically for cancer research, Verana Health's oncology datasets and analytics deliver clinically rich insights across tumor types and lines of therapy, supporting evidence generation at every stage of the drug development and commercialization lifecycle.

Abstracted Data

ABSTRACTED	ACCESSIBLE	ABSTRACTED + ACCESSIBLE
7,590	13,910+	21,500+

Potential patients as of Q3 2026

Note: Abstracted data is available for immediate delivery. Accessible data requires additional curation.

Clinician-led and AI-enabled oncology data platform

Verana Health securely ingests, links, and curates raw oncology care data from point-of-care clinical encounters. Purpose-built, fit-for-purpose data is designed to support rigorous research and confident decision-making across the oncology lifecycle.

Ingest Data
Structured and unstructured oncology EHR data are captured and de-identified, preserving clinical nuance from real-world care delivery.

Link Data
Data are harmonized and tokenized across EHR systems and linked with complementary sources, including claims data, biomarker and genomic data, and other relevant clinical inputs.

Curate Data
Data are clinically abstracted, quality-controlled, and continuously curated using expert oncology oversight and technology.

Curated, High-Quality Oncology Data
Available across multiple tumor types and treatment settings, including:

Hematologic cancers:
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma

Solid tumor cancers:
- Breast Cancer
- Colon Cancer
- Rectal Cancer
- Gastric Cancer
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer

Verana Health®

DATASHEET
Acute Myeloid Leukemia

Abstracted Data Summary:

DATA SET QUALITY

2.9 yrs	Average length of follow-up
21.5	Performance statuses on avg. per patient
77%	Patients with performance Status
10%	of AML patients transformed from MDS
97%	Patients with race data
92%	Patients with ethnicity data
82%	Patients with outcome data

TREATMENT HIGHLIGHTS

Autologous Transplant	23
Allogeneic Transplant	2,487
Received Venetoclax	2,438

MOLECULAR FEATURES

FLT3-ITD	1,127
FLT3-TKD	444

3,068 Relapse/ Refractory — Total **7,590**

About Verana Health

Verana Health, Inc.® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

© 2026 Verana Health | Datasheet | Acute Myeloid Leukemia | October 2026